EGFR and lung carcinoma: Targeting activating mutations in the tyrosine kinase epidermal growth factor receptor (EGFR) represents a success story in the treatment of lung cancer, a very commonly diagnosed malignancy that remains the leading cause of cancer-related mortality (Figure 1A) [1].